KMP / Board / Auditor Changes
Not Specified
Dividend Declaration or Non-Declaration
Not Specified
Board Meeting Outcomes
Not Specified
Financial Results (Standalone & Consolidated)
Not Specified
Disinvestment / Strategic Actions
Not Specified
Other Operational / Legal / Strategic Disclosures
General Company Information
- Corporate Identity Number: L24239DL2004PLC125888
- Year of Incorporation: 2004
- Corporate Office: Akums House, Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I, Delhi -110083
- Contact: Email: cs@akums.net, Telephone: 011-69041000 (Extn: 8676)
- Reporting Financial Year: FY 2025-26
- Stock Exchanges: BSE Limited and National Stock Exchange of India
- Paid-up Capital: ₹31,47,87,976
- BRSR Contact: Dharamvir Malik, Company Secretary and Compliance Officer
- Reporting Boundary: Consolidated
- Assurance Provider: BDO India Services Private Limited
- Assurance Type: Reasonable Assurance for Core Indicators, Limited Assurance for Essential (Other than Core) and Leadership Indicators
Business Activities
- Primary Business: Pharmaceutical formulations (NIC Code: 2100)
- Contribution to Turnover: 100%
- Operations: 14 plants and 5 offices nationally (19 locations total), no international operations
- Markets Served: Pan-India (28 states and 8 union territories), International (72 countries)
- Export Contribution: 4.4% of total turnover
- Customer Segments: Pharmaceutical companies, FMCG companies, Healthcare providers, Distribution network, Global markets, Government and regulatory interfaces
Employee Statistics
- Total Employees: 6,455 (Permanent: 6,455; Other than permanent: 0)
- Male: 5,732 (88.80%), Female: 723 (11.20%)
- Total Workers: 11,555 (Permanent: 882; Other than permanent: 10,673)
- Male: 7,953 (68.83%), Female: 3,602 (31.17%)
- Differently Abled: 13 employees (Male: 12, Female: 1), 18 workers (Male: 17, Female: 1)
- Gender Representation: Board of Directors - 1 female out of 8 members (12.50%), Key Management Personnel - 0 females out of 5 members
- Turnover Rates (FY 2025-26): Permanent Employees - 31.38% (Male: 31.18%, Female: 33.03%), Permanent Workers - 37.56% (Male: 36.97%, Female: 57.14%)
Subsidiary Companies
1. Pure & Cure Healthcare Private Limited (100% WOS) - Participates in Business Responsibilities
2. Maxcure Nutravedics Limited (100% WOS) - Participates
3. Malik Lifesciences Private Limited (100% WOS) - Participates
4. Akums Healthcare Limited (100% WOS) - Participates
5. Qualymed Pharma Private Limited (100% WOS) - Does not participate
6. Akumentis Healthcare Limited (91.50% Subsidiary) - Participates
7. Unosource Pharma Limited (100% WOS) - Participates
8. Sarvagunaushdhi Private Limited (100% WOS) - Does not participate
9. Plenteous Pharmaceuticals Limited (100% WOS) - Does not participate
10. Nicholas Healthcare Limited (100% WOS) - Does not participate
11. Upadhrish Reserchem LLP (100% WOS) - Participates
12. Medibox Pharma Private Limited (100% Step Down Subsidiary) - Does not participate
13. Akums Healthcare UK Limited (100% WOS) - Does not participate
14. Akums Healthcare Malta Private Limited (100% WOS) - Does not participate
15. Akums Healthcare (Zambia) Private Limited (51% JV with Government of Zambia) - Does not participate
CSR Applicability
- CSR Applicable: Yes
- Turnover: ₹1,348.74 Crores
- Net Worth: ₹2,305.25 Crores
Grievance Redressal (FY 2025-26)
- Communities: 0 complaints filed, 0 pending - Resolved through in-person interactions
- Investors: 0 complaints filed, 0 pending - Mechanism via email cs@akums.net
- Shareholders: 0 complaints filed, 0 pending - Mechanism via SCORES platform or email
- Employees and Workers: 8.00 complaints filed, 0 pending - 100% cases closed through various channels including dedicated HR teams
Material Responsible Business Conduct Issues
Environmental Issues:
1. Water Management (Risk) - Water scarcity and pollution impacts production
2. Waste Management (Risk) - Regulatory changes and disposal challenges
3. Climate Change (Risk) - Impacts raw material availability and processes
4. Raw Material Sourcing (Opportunity) - Sustainable sourcing avoids disruptions
5. Renewable Energy (Opportunity) - Reduces carbon footprint and costs
6. Energy Management (Opportunity) - Ensures compliance and cost savings
7. Emissions Management (Risk) - Climate change impacts business continuity
Social Issues:
8. Occupational Health & Safety (Risk) - Health impacts may disrupt operations
9. Sustainable Supply Chain (Opportunity) - Ethical sourcing mitigates disruptions
10. Protection of Human Rights (Risk) - Violations may result in legal liabilities
11. Product Quality, Safety & Recall Management (Risk) - Inadequate controls may lead to recalls
12. Health Education & Prevention (Opportunity) - Creates long-term societal value
13. Corporate Governance, Business Ethics, Integrity & Transparency (Opportunity) - Avoids legal issues and builds trust
14. Consumer & Patient Safety & Pharmacovigilance (Opportunity) - Ensures safety and maintains trust
15. Combating Counterfeit Medicines (Risk) - Counterfeit drugs may harm patients
Policy Coverage
- The company has multiple policies covering all 9 NGRBC Principles including Sustainability Policy, Energy and Carbon Policy, Environmental & Social Responsibility Policy, Human Rights Policy, Anti-Corruption Policy, Risk Management Policy, Whistle Blower Policy, and others
- All policies have been approved by the Board and are available at: https://www.akums.in/investors/corporate-governance-policies/
- Policies have been translated into procedures but do not yet extend to value chain partners (currently evaluating framework)
Certifications and Standards
- EU GMP, FSSAI, D.C.G.I, ISO 50001:2018, ISO 9001:2015, NSF International, USFDA, ISO 22000:2018, ISO 45001:2018, ISO 14001:2015
Governance and Leadership
- Highest Authority for BRSR Implementation: Sandeep Jain, Managing Director
- Board Committee for Sustainability: Managing Director oversees sustainability matters
- Director Statement: Sandeep Jain highlighted ESG challenges including environmental impact management, supply chain sustainability, product quality standards, and workforce health and safety
Performance Against Principles
Principle 1 (Ethical, Transparent, Accountable):
- Training coverage: Board of Directors (100%), KMP (100%), Employees (100%), Workers (100%)
- Fines/Penalties: ₹99,999 for misbranding (FSSAI), ₹40,000 for GST demand (subsidiary), ₹5,95,000 for SEBI LODR non-compliance
- Anti-corruption policy in place
- Accounts payable days: 71 days (FY 2025-26) vs 80 days (FY 2024-25)
- Related party transactions: Purchases 22.06%, Sales 11.04%, Loans & advances 96.03%, Investments 32.81%
Principle 2 (Sustainable and Safe Goods/Services):
- R&D investment in ESG technologies: 1.58% of total R&D
- Capex investment in ESG technologies: 6.49% of total capex
- Sustainable sourcing procedures: Not yet formalized
- Waste reclamation processes in place for plastics, e-waste, hazardous waste, and other waste
- EPR applicable and compliant
Principle 3 (Employee Well-being):
- Health insurance coverage: Employees 84.54%, Permanent workers 69%, Other workers 0%
- Accident insurance: Permanent employees 100%, Permanent workers 100%
- Maternity benefits: Female permanent workers 100%, Female other workers 100%
- Paternity benefits: Male permanent workers 100%, Male other workers 99%
- Day care facilities: All employees and workers 100%
- Retirement benefits: PF (employees 100%, workers 100%), Gratuity (employees 100%, workers 100%), ESI (employees 15.46%, workers 94.70%)
- Workplace accessibility: Enhanced with ramps, lifts, wheelchair access
- Equal opportunity policy in place
- Return to work rate after parental leave: 100% for all categories
- Grievance mechanisms available for all employee categories
- Training provided: 12,942 programs for employees, 7,244 for workers
- Performance reviews: 100% coverage for all employees and workers
- Occupational health and safety system: ISO 45001:2018 certified
- Safety incidents: Total recordable injuries - workers 1.17, employees 1; Fatalities - workers 33, employees 0
Principle 4 (Stakeholder Responsiveness):
- Stakeholder identification process includes internal and external groups
- Engagement with shareholders/investors (quarterly/annually), regulators (as required), customers (ongoing/annual), employees/workers (monthly/ongoing), suppliers (as required), communities (periodic/as required)
Principle 5 (Human Rights):
- Human rights training: Employees 8.52% coverage, Workers 13.21% coverage
- Minimum wage compliance: Majority paid above minimum wage
- Median remuneration: BoD Executive ₹861.93 lakh, BoD Non-Executive ₹22 lakh, KMP ₹120.88 lakh, Employees ₹41,500, Workers ₹14,887
- Gross wages to females: 15.77% of total wages
- Human rights focal point: HR function
- Complaints: Sexual harassment 4, Discrimination 0, Child labour 0, Forced labour 0, Wages 0
- POSH complaints: 4 total reported
Principle 6 (Environmental Protection):
- Energy consumption: Total 10,96,245.52 GJ, Renewable 3,36,446.52 GJ, Non-renewable 7,59,799.00 GJ
- Energy intensity: 251.49 GJ/₹ crore revenue
- Water withdrawal: 11,34,998.46 KL (100% groundwater)
- Water consumption: 10,30,757.57 KL
- Water intensity: 236.47 KL/₹ crore revenue
- Water discharge: 1,04,240.89 KL to third parties with treatment
- Zero Liquid Discharge: Implemented at 3 manufacturing sites
- Air emissions: SOx 7.50 MT, PM 22.59 MT, CO 1,882.11 MT
- GHG emissions: Scope 1 17,925.07 MT CO2e, Scope 2 1,20,256.33 MT CO2e
- Emission reduction projects: Renewable energy integration, clean fuel transition, electrification of logistics
- Waste management: Total 9,204.67 MT, Recycled/Re-used/Recovered 6,591.61 MT, Disposed 2,452.03 MT
- Environmental compliance: Fully compliant with all applicable laws
Principle 7 (Responsible Policy Influence):
- affiliations: Indian Drug Manufacturers Association, SIDCUL Manufacturers Association, Confederation of Indian Industry, Association of Pharmaceuticals Manufacturers
- No anti-competitive conduct issues
Principle 8 (Inclusive Growth):
- No social impact assessments or R&R projects in FY 2025-26
- Community grievance mechanisms in place (0 grievances recorded)
- MSME sourcing: 37.01% of input material
- Domestic sourcing: 89.39% from within India
- Job creation: 7.38% wages in rural areas, 72.61% in semi-urban areas
- CSR in aspirational districts: ₹1,786,289 spent in Haridwar, Uttarakhand
- CSR beneficiaries: Multiple programs including eye camps, blood donation, health camps, skill enhancement, plantation, cleanliness drives
Principle 9 (Responsible Consumer Engagement):
- Consumer complaint mechanisms via email, telephone, web portal
- Product information: 100% carry safe usage information
- Consumer complaints: 1,066 total (163 pending)
- Product recalls: 1 voluntary recall due to stability observation
- Cyber security and data privacy framework in place
- Data breaches: 0 instances
- Product information displayed as per regulatory requirements
Independent Assurance Statement by BDO India
- Assurance Standard: ISAE 3000 (Revised) and ISAE 3410
- Scope: India operations, BRSR Core Indicators (Reasonable Assurance), Other than Core Indicators (Limited Assurance)
- Methodology: Physical and virtual verification at 4 locations, review of data collection and calculation methodologies
- Observations: Disclosures fairly reliable, minor discrepancies corrected, recommendation for standardized data protocols
- Conclusion: Reasonable assurance for Core indicators, Limited assurance for other indicators
- Date: June 15, 2026
- Signed: Indra Guha, Partner- Sustainability & ESG Business Advisory Services